Vertex Pharmaceuticals (VRTX) has been, and will continue to be the leader in therapy for people with Cystic Fibrosis. Below is an update of all the different drugs in clinical trials that the company is currently running, including deuterated ivacaftor (VX-561), formerly known as CTP-656 that was purchased for $160 million from Concert Pharmaceuticals in July. Concert is eligible for up to $90 million more, dependent upon how far VX-561 progresses.
Twice Daily
Ivacaftor
Ivacaftor + Lumacaftor
Ivacaftor + Tezacaftor
Twice Daily Triple Combo Phase 2
Ivacaftor + Tezacaftor + VX-440
Ivacaftor + Tezacaftor + VX-152
Ivacaftor + Tezacaftor + VX-659
Ivacaftor + Tezacaftor + VX-445
Once Daily Triple Combo Phase 2
VX-561 + Tezacaftor + VX-659 readout March 2018
VX-561 + Tezacaftor + VX-445 readout April 2018
The Ivacaftor patent runs to 2027, the Deuterated Ivacaftor (VX-561) patent runs into 2031. The goal for the program is to create a triple combo (1 potentiator, 2 correctors) once daily dosing for the majority of CF people with the F508del mutation. The company plans to run phase 3 triple combo trials in 2018. Thank you for reading.
Twice Daily
Ivacaftor
Ivacaftor + Lumacaftor
Ivacaftor + Tezacaftor
Twice Daily Triple Combo Phase 2
Ivacaftor + Tezacaftor + VX-440
Ivacaftor + Tezacaftor + VX-152
Ivacaftor + Tezacaftor + VX-659
Ivacaftor + Tezacaftor + VX-445
Once Daily Triple Combo Phase 2
VX-561 + Tezacaftor + VX-659 readout March 2018
VX-561 + Tezacaftor + VX-445 readout April 2018
The Ivacaftor patent runs to 2027, the Deuterated Ivacaftor (VX-561) patent runs into 2031. The goal for the program is to create a triple combo (1 potentiator, 2 correctors) once daily dosing for the majority of CF people with the F508del mutation. The company plans to run phase 3 triple combo trials in 2018. Thank you for reading.
No comments:
Post a Comment